Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Yaroslav Dmytrenko
Yaroslav Dmytrenko

Vir Biotechnology delivers clinical milestones in hepatitis delta with ECLIPSE 1 and SOLSTICE studies

Vir Biotechnology delivers clinical milestones in hepatitis delta with ECLIPSE 1 and SOLSTICE studies
Vir Biotechnology hepatitis delta trials

Vir Biotechnology announced that its ECLIPSE 1 clinical study achieved all endpoints, while the SOLSTICE trial demonstrated deep and sustained viral suppression for patients with hepatitis delta.

The company described these results as milestones in its push to transform the treatment landscape for people living with the disease.

Vir Biotechnology previously advanced its Phase 3 ECLIPSE program for a potential hepatitis delta treatment, targeting unmet medical needs, as detailed here. The company also entered a multi-program partnership with Gilead Sciences to develop solid tumor therapies using dual-masked TCEs, according to an earlier announcement. These initiatives highlight ongoing efforts to diversify Vir's pipeline.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Buterin’s new vision: Why Ethereum wants to become digital gold
  • By Olena Litvinenko
  • 19 hours ago
Buterin’s new vision: Why Ethereum wants to become digital gold
Editors' Picks
From affair to market crash: How the Nvidia scandal hit Bitcoin
  • By Anastasiia Chabaniuk
  • 23 hours ago
From affair to market crash: How the Nvidia scandal hit Bitcoin
Editors' Picks
Shield AI’s Echodyne deal and the global counter-drone race
  • By Dmytro Kharkov
  • Yesterday
Shield AI’s Echodyne deal and the global counter-drone race
Editors' Picks
All Editors' Top Picks

Latest Vir Biotechnology News

Vir Biotechnology meets primary endpoint in Phase 3 ECLIPSE 1 trial for chronic Hepatitis Delta
  • By Mikhail Vnuchkov
  • Yesterday
Vir Biotechnology meets primary endpoint in Phase 3 ECLIPSE 1 trial for chronic Hepatitis Delta
Companies
#Vir Biotechnology
Vir Biotechnology advances pipeline with Phase 3 ECLIPSE 1 topline data approaching
  • By Pavlo Kot
  • 05.11.2026
Vir Biotechnology advances pipeline with Phase 3 ECLIPSE 1 topline data approaching
Companies
#Vir Biotechnology
Vir Biotechnology advances dual-masked TCE pipeline targeting difficult-to-treat solid tumors
  • By Ksenia Gerey
  • 22.10.2026
Vir Biotechnology advances dual-masked TCE pipeline targeting difficult-to-treat solid tumors
Companies
#Vir Biotechnology
All Vir Biotechnology News
  • Olena Litvinenko
  • 19 hours ago
Buterin’s new vision: Why Ethereum wants to become digital gold
  • Anastasiia Chabaniuk
  • 23 hours ago
From affair to market crash: How the Nvidia scandal hit Bitcoin
  • Dmytro Kharkov
  • Yesterday
Shield AI’s Echodyne deal and the global counter-drone race
  • Pavlo Kot
  • 08.11.2026
From airline tickets to Ferraris: What can you buy with crypto?
  • Pavlo Kot
  • 07.11.2026
Apartment or Bitcoin: Choosing a safe haven for your wealth
  • Yulia Slavina
  • 39 min ago
Javier Blas: Legal dispute over oil tanker benchmark exposes tensions in City of London institution
  • Yulia Slavina
  • 1 hour ago
Altcoin volume cools to normal levels after September surge, Alan Rogers notes
  • Mykhailo Ihnatenko
  • 1 hour ago
Jordan Kerridge: Altcoin trading volume returns to normal after outpacing Bitcoin
  • Eugene Komchuk
  • 2 hours ago
Kevin Susanto: Attending Binance Blockchain Week Thailand and looking to connect with industry peers
  • Daria Chernytska
  • 2 hours ago
Mark Sobel: China signals slower RMB appreciation as undervaluation persists
Top News
  • Olga Shendetskaya
  • 46 min ago
Trump delays new Iran strikes but keeps Strait of Hormuz blockade
Trump delays new Iran strikes but keeps Strait of Hormuz blockade
  • Eugene Komchuk
  • 1 hour ago
Trump's company earns $410 million from cryptocurrency ventures
Trump's company earns $410 million from cryptocurrency ventures
  • Ksenia Gerey
  • 17 hours ago
Anthropic has no plans to delay IPO despite market selloff
Anthropic has no plans to delay IPO despite market selloff
  • Eugene Komchuk
  • 19 hours ago
Hedge funds begin massive selloff of technology stocks
Hedge funds begin massive selloff of technology stocks
  • Oleg Tkachenko
  • 22 hours ago
U.S. authorities grant Coinbase a banking charter
U.S. authorities grant Coinbase a banking charter
Live News
  • Mykhailo Ihnatenko
  • Now
Ethereum price prediction: Can $2,000 support hold ahead of U.S. CPI?
  • Mélissa Bac
  • Now
Strategy buys $82 million in Bitcoin, raises holdings to 850,364 BTC
  • Mykhailo Ihnatenko
  • Now
Nvidia stock falls amid CEO scrutiny: Can buyers reclaim $178?
  • Anton Kharitonov
  • Now
EUR/USD targets 1.1200 as dollar weakens ahead of U.S. inflation data
  • Mykhailo Ihnatenko
  • Now
Ethereum slides as geopolitical risks trigger another $1B liquidation wave
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers